Data / Form D filings / Ascendis Pharma A/S
Ascendis Pharma A/S: Form D filing
Ascendis Pharma A/S, a pharmaceuticals company in Hellerup, Denmark, filed a Form D with the SEC in 2014. The latest, on December 9, 2014, reports $60 million sold of a $60 million offering to 11 investors.
Find out what Ascendis Pharma A/S does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- TUBORG BOULEVARD 12, Hellerup, Denmark, DK-29
- Phone
- (453) 694-4486
- Industry
- Pharmaceuticals
- Entity type
- Other (Public Limited Liability Company)
- Incorporated in
- Denmark
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1612042
The full lists. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 9, 2014 | New notice | $59,999,974 | $59,999,974 | $0 | 11 | Nov 24, 2014 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| James Wolff Healy | Director | |
| Grethe Wolff Rasmussen | Executive Officer | |
| Harald Wolff Rau | Executive Officer | |
| Rafa?le Wolff Tordjman | Director | |
| Martin Wolff Olin | Director | |
| Jan M?ller Mikkelsen | Executive Officer, Director | |
| Lotte Wolff S?nderbjerg | Executive Officer | |
| Martin Wolff Auster | Executive Officer | |
| Jonathan Wolff Silverstein | Director | |
| Michael Wolff Jensen | Executive Officer, Director | |
| Michael Wolff Mayer | Director | |
| Edwin Wolff de Graaf | Director | |
| Thomas Wolff Soloway | Executive Officer | |
| Albert Wolff Cha | Director |
Every Form D from the week of Dec 8, 2014 · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Ascendis Pharma A/S reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.